These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 34241561)

  • 1. Challenges of non-clinical safety testing for biologics: A Report of the 9th BioSafe European Annual General Membership Meeting.
    Kissner T; Blaich G; Baumann A; Kronenberg S; Hey A; Kiessling A; Schmitt PM; Driessen W; Carrez C; Kramer D; Fretland J; Richter WF; Paehler T; Hopfer U; Rattel B
    MAbs; 2021; 13(1):1938796. PubMed ID: 34241561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current strategies in the non-clinical safety assessment of biologics: New targets, new molecules, new challenges.
    Brennan FR; Andrews L; Arulanandam AR; Blumel J; Fikes J; Grimaldi C; Lansita J; Loberg LI; MacLachlan T; Milton M; Parker S; Tibbitts J; Wolf J; Allamneni KP
    Regul Toxicol Pharmacol; 2018 Oct; 98():98-107. PubMed ID: 30026135
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-clinical Safety Evaluation of Biotherapeutics - Challenges, Opportunities and new Insights.
    Blaich G; Baumann A; Kronenberg S; de Haan L; Ulrich P; Richter WF; Tibbitts J; Chivers S; Tarcsa E; Caldwell R; Crameri F
    Regul Toxicol Pharmacol; 2016 Oct; 80S():S1-S14. PubMed ID: 27578450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biotherapeutics in non-clinical development: Strengthening the interface between safety, pharmacokinetics-pharmacodynamics and manufacturing.
    Ulrich P; Blaich G; Baumann A; Fagg R; Hey A; Kiessling A; Kronenberg S; Lindecrona RH; Mohl S; Richter WF; Tibbitts J; Crameri F; Weir L
    Regul Toxicol Pharmacol; 2018 Apr; 94():91-100. PubMed ID: 29355662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical Development of Biologics: Integrating Safety, Pharmacokinetics, and Pharmacodynamics to Create Smarter and More Flexible Nonclinical Safety Programs Optimizing Animal Use.
    Hey A; Baumann A; Kronenberg S; Blaich G; Mohl S; Fagg R; Ulrich P; Rattel B; Richter WF; Kiessling A; Weir L
    Int J Toxicol; 2021; 40(3):270-284. PubMed ID: 33631988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New challenges and opportunities in nonclinical safety testing of biologics.
    Baumann A; Flagella K; Forster R; de Haan L; Kronenberg S; Locher M; Richter WF; Theil FP; Todd M
    Regul Toxicol Pharmacol; 2014 Jul; 69(2):226-33. PubMed ID: 24755365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonclinical safety testing of biopharmaceuticals--Addressing current challenges of these novel and emerging therapies.
    Brennan FR; Baumann A; Blaich G; de Haan L; Fagg R; Kiessling A; Kronenberg S; Locher M; Milton M; Tibbitts J; Ulrich P; Weir L
    Regul Toxicol Pharmacol; 2015 Oct; 73(1):265-75. PubMed ID: 26219199
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current challenges and opportunities in nonclinical safety testing of biologics.
    Kronenberg S; Baumann A; de Haan L; Hinton HJ; Moggs J; Theil FP; Wakefield I; Singer T
    Drug Discov Today; 2013 Dec; 18(23-24):1138-43. PubMed ID: 23942260
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Considerations for the nonclinical safety evaluation of antibody drug conjugates for oncology.
    Roberts SA; Andrews PA; Blanset D; Flagella KM; Gorovits B; Lynch CM; Martin PL; Kramer-Stickland K; Thibault S; Warner G
    Regul Toxicol Pharmacol; 2013 Dec; 67(3):382-91. PubMed ID: 24012707
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
    Krause S; Lacana E; Welch J; Shapiro M; Downey C; Chung J; Zhou Q; Van Der Plas M; Depatie C; Ingram B; Srebalus-Barnes C; Polozova A; Rellahan B; Choi D; Burdick R; Stangler T; Shacter E
    PDA J Pharm Sci Technol; 2019; 73(4):401-416. PubMed ID: 31004040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From the History of the Croatian Dermatovenereological Society - The Croatian Medical Association and an Overview of Important Information Regarding the Journal Acta Dermatovenerologica Croatica.
    Dobrić I
    Acta Dermatovenerol Croat; 2018 Dec; 26(4):344-348. PubMed ID: 30665489
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of pharmacokinetic/ pharmacodynamic modelling for starting dose selection in first-in-human trials of high-risk biologics.
    Agoram BM
    Br J Clin Pharmacol; 2009 Feb; 67(2):153-60. PubMed ID: 19076987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Developmental toxicology: new directions workshop: refining testing strategies and study designs.
    Brannen KC; Fenton SE; Hansen DK; Harrouk W; Kim JH; Shuey D
    Birth Defects Res B Dev Reprod Toxicol; 2011 Oct; 92(5):404-12. PubMed ID: 22006510
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New horizons in bladder cancer research.
    Boormans JL; Zwarthoff EC; Black PC; Goebell PJ; Kamat AM; Nawroth R; Seiler R; Williams SB; Schmitz-Dräger BJ
    Urol Oncol; 2020 Dec; 38(12):867-885. PubMed ID: 30852032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meeting report of the 3rd European Biotransformation Workshop.
    Walles M; Pähler A; Isin EM; Ahlqvist MM
    Xenobiotica; 2023 Feb; 53(2):123-127. PubMed ID: 36692101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug safety Africa: An overview of safety pharmacology & toxicology in South Africa.
    Guth BD; Grobler AF; Frazier KS; Greiter-Wilke A; Herzyk D; Hough TA; Khan AA; Markert M; Smith JD; Svenson KL; Wells S; Pugsley MK
    J Pharmacol Toxicol Methods; 2019; 98():106579. PubMed ID: 31085319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-human primates in the PKPD evaluation of biologics: Needs and options to reduce, refine, and replace. A BioSafe White Paper.
    Ménochet K; Yu H; Wang B; Tibbitts J; Hsu CP; Kamath AV; Richter WF; Baumann A
    MAbs; 2022; 14(1):2145997. PubMed ID: 36418217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alternatives to Monkey Reproductive Toxicology Testing for Biotherapeutics.
    Hoberman AM; Maki K; Mikashima F; Naota M; Wange RL; Lansita JA; Weis SL
    Int J Toxicol; 2023 Dec; 42(6):467-479. PubMed ID: 37714565
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.